122 related articles for article (PubMed ID: 25391240)
1. Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia.
Abraham A; Devasia AJ; Varatharajan S; Karathedath S; Balasubramanian P; Mathews V
Ann Hematol; 2015 May; 94(5):883-5. PubMed ID: 25391240
[No Abstract] [Full Text] [Related]
2. In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine.
Onetto N; Momparler RL; Momparler LF; Gyger M
Semin Oncol; 1987 Jun; 14(2 Suppl 1):231-7. PubMed ID: 2438776
[No Abstract] [Full Text] [Related]
3. Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia.
Colly LP; Peters WG; Richel D; Arentsen-Honders MW; Starrenburg CW; Willemze R
Semin Oncol; 1987 Jun; 14(2 Suppl 1):257-61. PubMed ID: 3035720
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic studies on possible improvement of cytosine arabinoside treatment.
Mejer J
Scand J Clin Lab Invest; 1981 Feb; 41(1):29-34. PubMed ID: 6942484
[TBL] [Abstract][Full Text] [Related]
5. Enzymology of cytosine arabinoside.
Cheng YC; Capizzi RL
Med Pediatr Oncol; 1982; 10 Suppl 1():27-31. PubMed ID: 7162464
[No Abstract] [Full Text] [Related]
6. Effect of cell growth and cell differentiation on 1-beta-D-arabinofuranosylcytosine metabolism in myeloid cells.
Chiba P; Tihan T; Eher R; Köller U; Wallner C; Göbl R; Linkesch W
Br J Haematol; 1989 Apr; 71(4):451-5. PubMed ID: 2713269
[TBL] [Abstract][Full Text] [Related]
7. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
8. Lack of cross-resistance between cytosine arabinoside and a new halogenated nucleoside analogue, 2-bromo-2'-deoxyadenosine in human acute myeloid leukaemia cells.
Pemble LB; Lihou MG; Blakley RL; Jamieson GP; Smith PJ
Cancer Chemother Pharmacol; 1987; 20(2):155-61. PubMed ID: 3499252
[TBL] [Abstract][Full Text] [Related]
9. Studies on mechanisms of resistance to cytosine arabinoside: problems in the determination of related enzyme activities in leukemic cells.
Coleman CN; Johns DG; Chabner BA
Ann N Y Acad Sci; 1975 Aug; 255():247-51. PubMed ID: 171992
[No Abstract] [Full Text] [Related]
10. In vivo development of cytosine arabinoside resistance in the BN acute myelocytic leukemia.
Hagenbeek A; Martens AC; Colly LP
Semin Oncol; 1987 Jun; 14(2 Suppl 1):202-6. PubMed ID: 3473677
[TBL] [Abstract][Full Text] [Related]
11. Reduction of ara-C cytotoxicity in HL 60 cells by addition of deoxycytidine, cytidine or increased level of cytidine deaminase.
Mejer J; Mortensen BT
Adv Exp Med Biol; 1989; 253B():335-9. PubMed ID: 2558539
[No Abstract] [Full Text] [Related]
12. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.
Chabot GG; Bouchard J; Momparler RL
Biochem Pharmacol; 1983 Apr; 32(7):1327-8. PubMed ID: 6189497
[No Abstract] [Full Text] [Related]
14. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.
Xu PP; Chen BA; Feng JF; Cheng L; Xia GH; Li YF; Qian J; Ding JH; Lu ZH; Wang XM; Xu K; Schultz M
Chin Med J (Engl); 2012 Jun; 125(12):2137-43. PubMed ID: 22884143
[TBL] [Abstract][Full Text] [Related]
15. Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy.
Harris AL; Grahame-Smith DG; Potter CG; Bunch C
Clin Sci (Lond); 1981 Feb; 60(2):191-8. PubMed ID: 6940687
[TBL] [Abstract][Full Text] [Related]
16. Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo.
Chiba P; Tihan T; Szekeres T; Salamon J; Kraupp M; Eher R; Köller U; Knapp W
Leukemia; 1990 Nov; 4(11):761-5. PubMed ID: 2232889
[TBL] [Abstract][Full Text] [Related]
17. Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia.
Banklau C; Jindadamrongwech S; Sawangpanich R; Apibal S; Hongeng S; Paisooksantivatana K; Pakakasama S
Hematol Oncol Stem Cell Ther; 2010; 3(3):103-8. PubMed ID: 20890066
[TBL] [Abstract][Full Text] [Related]
18. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
Reuter C; Auf der Landwehr U; Schleyer E; Zühlsdorf M; Ameling C; Rolf C; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1994 Feb; 8(2):217-25. PubMed ID: 8309245
[TBL] [Abstract][Full Text] [Related]
19. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival.
Mahlknecht U; Dransfeld CL; Bulut N; Kramer M; Thiede C; Ehninger G; Schaich M
Leukemia; 2009 Oct; 23(10):1929-32. PubMed ID: 19458626
[No Abstract] [Full Text] [Related]
20. Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines.
Rathe SK; Largaespada DA
Leukemia; 2010 Aug; 24(8):1513-5. PubMed ID: 20508618
[No Abstract] [Full Text] [Related]
[Next] [New Search]
